Financial Performance - The company's revenue for Q1 2023 was ¥649,826,753.50, representing a 38.73% increase compared to ¥468,422,199.36 in the same period last year[12]. - Net profit attributable to shareholders reached ¥162,393,315.01, a significant increase of 334.85% from ¥37,345,056.26 year-over-year[12]. - The basic earnings per share (EPS) was ¥1.09, up 230.30% from ¥0.33 in the previous year[12]. - The company's operating revenue for the reporting period was RMB 649.83 million, an increase of 38.73% compared to the previous period, primarily due to the expansion of new hospitals and increased sales scale[29]. - Net profit for the current period was ¥165,334,547.22, representing a substantial increase of 44.73% compared to ¥37,345,056.26 in the previous period[57]. - The company reported a basic and diluted earnings per share of ¥1.09, up from ¥0.33 in the previous period[57]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,129,697,823.92, reflecting a 12.31% increase from ¥3,676,965,643.95 at the end of the previous year[12]. - The total liabilities amounted to RMB 1.88 billion, compared to RMB 1.61 billion in the previous period[21]. - The total equity attributable to the parent company was RMB 2.23 billion, compared to RMB 2.07 billion in the previous period[21]. - Cash and cash equivalents at the end of the period totaled ¥932,964,231.47, up from ¥113,604,394.24 at the beginning of the period, reflecting a net increase of ¥6,734,399.75[51]. - The total assets at the end of the period reached $4.13 billion, up from $3.68 billion, indicating a growth of 12.2%[61]. - Non-current assets totaled $2.69 billion, up from $2.49 billion, representing an increase of 8.0%[61]. Cash Flow - The net cash flow from operating activities was ¥120,447,583.12, a slight decrease of 2.10% from the previous year[12]. - The net cash flow generated from operating activities was RMB 120.45 million, a decrease of 2.10% compared to the previous period, mainly due to increased costs[29]. - The net cash flow from operating activities was $120.45 million, slightly down from $123.03 million, a decrease of 2.1%[62]. - Cash outflow from investing activities was $209.01 million, compared to $265.09 million, showing a reduction of 21.1%[62]. - Cash inflow from financing activities was $182.80 million, down from $202.50 million, a decrease of 9.8%[62]. Expenses - Research and development expenses increased by 206.26% to ¥2,211,400.00, primarily due to increased spending on ophthalmology-related clinical applications and digital research[14]. - The company's management expenses for the reporting period were RMB 76.63 million, an increase of 12.42% compared to the previous period, primarily due to increased salaries and depreciation expenses[29]. - Total operating costs amounted to ¥549,611,128.83, up 30.94% from ¥419,861,898.34 in the prior period, primarily driven by a 40.04% increase in operating costs due to sales growth[38][59]. Acquisitions and Investments - The company completed the acquisition of 80% equity in Dongguan Guangming Eye Hospital[18]. - The company completed the acquisition of a 35% stake in Dongguan Guangming Eye Hospital, increasing its total ownership to 80%[45]. - The company's investment income for the reporting period was RMB 92.05 million, an increase of RMB 86.18 million compared to the previous period, mainly due to the revaluation of equity in Dongguan Guangming Eye Hospital[29]. Other Financial Metrics - The weighted average return on equity (ROE) improved to 7.56%, up from 3.86% in the previous year[12]. - The company experienced a 73.81% increase in taxes payable, primarily due to an increase in corporate income tax[14]. - The income tax expense for the current period was ¥23,978,782.96, a 46.39% increase from ¥16,379,916.00 in the previous period, mainly due to the increase in total profit[55]. - Other income increased to ¥2,418,412.98 from ¥1,646,244.94 in the previous period, indicating improved financial performance[38]. - The balance of goodwill at the end of the reporting period increased by 1440.08% compared to the beginning of the period, due to the conversion of an originally affiliated company into a non-same control enterprise[29]. - The balance of contract liabilities at the end of the reporting period increased by 45.07% compared to the beginning of the period, attributed to business scale growth[29]. - The balance of other payables at the end of the reporting period increased by 197.87% compared to the beginning of the period, due to increased operating expenses[29].
普瑞眼科(301239) - 2023 Q1 - 季度财报